Sands Capital, an investment management company, released its “Sands Capital Select Growth Fund” Q4 2024 investor letter. A ...

Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart ...

Edwards Lifesciences (NYSE:EW) recently announced significant findings at the ACC Annual Scientific Session, showcasing crucial research in the treatment of structural heart disease. This ...

Despite a solid Q4 earnings beat, Edwards Lifesciences' shares remain undervalued with a reduced P/E multiple of 33x. Read why EW stock is a Buy.

Edwards Lifesciences recently announced significant findings at the ACC Annual Scientific Session, showcasing crucial research in the treatment of structural heart disease. This development ...

Results from the EARLY TAVR trial — the first randomized, controlled FDA pivotal study designed to determine the best ...

Edwards Lifesciences Corp. closed 24.29% below its 52-week high of $95.73, which the company achieved on April 1st.

In a report released today, Rick Wise from Stifel Nicolaus maintained a Buy rating on Edwards Lifesciences (EW – Research Report), with a price ...

Edwards Lifesciences Corp. closed 25.77% short of its 52-week high of $96.12, which the company reached on March 28th.

Edwards Lifesciences beats profit estimate on strength in heart devices Edwards Lifesciences beat analysts' estimate for fourth-quarter profit on Tuesday, helped by strong demand for its ...

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. The company offers ...